

# Kevin Petrie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7087958/publications.pdf>

Version: 2024-02-01

46  
papers

3,690  
citations

394421

19  
h-index

345221

36  
g-index

51  
all docs

51  
docs citations

51  
times ranked

6504  
citing authors

#	ARTICLE	IF	CITATIONS
1	The biguanide polyamine analog verindamycin promotes differentiation in neuroblastoma via induction of antizyme. <i>Cancer Gene Therapy</i> , 2022, 29, 940-950.	4.6	3
2	The Protozoan Inhibitor Atovaquone Affects Mitochondrial Respiration and Shows In Vitro Efficacy Against Glucocorticoid-Resistant Cells in Childhood B-Cell Acute Lymphoblastic Leukaemia. <i>Frontiers in Oncology</i> , 2021, 11, 632181.	2.8	3
3	The RAR $\hat{1}$ <sup>3</sup> Oncogene: An Achilles Heel for Some Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3632.	4.1	12
4	Retinoic acid receptor $\hat{1}$ <sup>3</sup> is a therapeutically targetable driver of growth and survival in prostate cancer. <i>Cancer Reports</i> , 2020, 3, e1284.	1.4	19
5	The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. <i>Leukemia</i> , 2019, 33, 2628-2639.	7.2	27
6	Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1440.	4.1	7
7	A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1492.	4.1	10
8	Deregulated expression of HDAC9 in B-cells promotes development of lymphoproliferative disease and lymphoma. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1483-1495.	2.4	37
9	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. <i>Cancer Research</i> , 2016, 76, 3025-3035.	0.9	33
10	Abstract 4115: Inhibition of triple negative breast cancer cell invasion by the targeted interference of Sin3A function affecting Wnt and TGF $\hat{1}$ <sup>2</sup> signaling. , 2016, , .		0
11	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. <i>Cancer Cell</i> , 2015, 27, 72-84.	16.8	165
12	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 5100-5109.	7.0	49
13	Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1824-1836.	4.1	65
14	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. <i>Cancer Research</i> , 2015, 75, 3043-3053.	0.9	78
15	Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1363-1363.	1.4	11
16	Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma. <i>PLoS ONE</i> , 2015, 10, e0119834.	2.5	16
17	Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 34087-34105.	1.8	26
18	Abstract LB-160: HDAC9 expression is deregulated in malignant B-cell lymphomas in particular in diffuse large B-cell lymphoma and mantle cell lymphoma. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract LB-201: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically. , 2014, , .		0
20	Abstract 411: Targeted PF1, JARID1B inhibition induces epigenetic reprogramming in triple negative breast cancer. , 2014, , .		0
21	HDAC9 Expression Is Deregulated in Malignant B-Cell Lymphomas in Particular in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Blood, 2014, 124, 5374-5374.	1.4	1
22	New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK. Clinical Cancer Research, 2013, 19, 5814-5821.	7.0	119
23	Abstract LB-87: A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma.. , 2013, , .		0
24	Targeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressorâ€Like Protein. Science Translational Medicine, 2012, 4, 127ra38.	12.4	76
25	Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine, 2012, 18, 605-611.	30.7	584
26	Abstract 1826: Anti-tumorigenic effects by targeted functional disruption of the Sin3 PAH-2 domain. , 2012, , .		0
27	Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas. Blood, 2012, 120, 3505-3505.	1.4	0
28	Abstract 2826: Reversal of the basal phenotype in triple negative (TN) breast cancer using a SID decoy. , 2011, , .		1
29	Histone H3 Methylation Mediates All-Trans-Retinoic Acid Responsiveness in Acute Myeloid Leukemia. Blood, 2011, 118, 224-224.	1.4	0
30	Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11811-11816.	7.1	59
31	Abstract 572: Interference with Sin3 PAH-2 domain function induces epigenetic reprogramming, differentiation and growth inhibition in breast cancer cells. , 2010, , .		0
32	Differentiation therapy of acute myeloid leukemia: past, present and future. Current Opinion in Hematology, 2009, 16, 84-91.	2.5	147
33	Modulation of Histone H3K4 and H3K27 Methylation Levels Via Pharmacological Inhibition of LSD1 and Degradation of the EZH2-Containing Polycomb Repressive Complex 2 Stimulates ATRA-Mediated Differentiation of AML Cells.. Blood, 2009, 114, 1046-1046.	1.4	15
34	Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters. Oncogene, 2008, 27, 5260-5266.	5.9	10
35	Marked for death. Nature Cell Biology, 2008, 10, 507-509.	10.3	20
36	DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood, 2008, 111, 2374-2377.	1.4	46

#	ARTICLE	IF	CITATIONS
37	AML1/ETO, a promiscuous fusion oncoprotein. Blood, 2007, 109, 4109-4110.	1.4	4
38	Ectopic Expression of HDAC9 in Murine Lymphoid System Leads to Altered Lymphocyte Numbers and Proliferation as Well as Predisposition to Tumorigenesis.. Blood, 2007, 110, 376-376.	1.4	1
39	Retinoblastoma Protein and the Leukemia-Associated PLZF Transcription Factor Interact To Repress Target Gene Promoters.. Blood, 2007, 110, 1240-1240.	1.4	0
40	Histone Deacetylase Inhibitors in APL and Beyond. , 2007, 313, 157-203.		6
41	Mice Overexpressing Histone Deacetylase 9 Display Abnormal B Cell Development and Proliferation.. Blood, 2006, 108, 1433-1433.	1.4	0
42	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics, 2005, 37, 391-400.	21.4	1,710
43	Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor $\alpha$ and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression. Cancer Research, 2005, 65, 7856-7865.	0.9	11
44	The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms. Journal of Biological Chemistry, 2003, 278, 16059-16072.	3.4	128
45	Lineage restriction of the RARalpha gene expression in myeloid differentiation. Blood, 2001, 98, 2563-2567.	1.4	49
46	Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood, 2000, 96, 2557-2561.	1.4	106